Missions and Steering Committee

MISSIONS
-

The International Regulatory Peptide Society promotes scientific meetings and exchanges devoted to all aspects of basic and clinical research on regulatory peptides and related topics, thus keeping up the tradition of the International Symposia on Gut Hormones and Regulatory Peptides.

STEERING COMMITTEE
-

David Vaudry, PhD, HDR (CHAIR of IRPS)

INSERM Researcher, Contract Professor
University of Rouen
n 76821 Mont-Saint-Aignan
France
david.vaudry@univ-rouen.fr

David Vaudry joined the laboratory of Cellular and Molecular Neuroendocrinology in 1996. He was awarded a PhD in 2000 from the University of Rouen and then conducted a postdoc at the National Institute of Mental Health in Bethesda. In 2002, he was recruited as INSERM Researcher, and since 2008 he has been the head of the Inserm U982 team ‘Neuropeptides, Neuronal death and Cell plasticity’. His project is focused on the functional evaluation of the genes and proteins regulated by peptides during brain development or in adult pathologies such as Parkinson and Stroke. David Vaudry is also scientific director of the PRIMACEN cell imaging platform (http://www.primacen.fr) and deputy director of the PISSARO proteomics platform. He has published 140 research papers referenced in PubMed (4718 citations according to ISI Web of KNOWLEDGETM, h-index 33) in the fields of Neuroscience and Cell Signalling in international journals, including Journal of Neurochemistry, Molecular Neurobiology, PNAS, Science and Pharmacological Reviews. From 2012 to 2015, he was General Secretary of the French Neuroendocrine Society. He is currently the coordinator of the LARC-Neuroscience Network (http://larc-neurosciences.org). In 2016, David Vaudry was organizer of the RegPep2016 in Rouen (www.regpep2016.fr).

—OOO—

Mario Delgado, PhD

Instituto de Parasitologia y Biomedicina, CSIC
Granada, Spain
mdelgado@ipb.csic.es

Mario Delgado is Full Professor of the Spanish National Reseach Council (CSIC) and Director of the Institute of Parasitology and Biomedicine IPBLN-CSIC, Granada, Spain. His main research focus is on neuropeptides and hormones with functions in the immune system with an emphasis on the design of new therapies for the treatment of inflammatory and autoimmune disorders.

 

 

Inge Depoortere, PhD

Gut Peptide Research Group, Translational Research Center for Gastrointestinal Disorders
Leuven, Belgium
Inge.Depoortere@med.kuleuven.be

Inge Depoortere is Professor at the “Gut Peptide Research Lab” of the Translational Research Center for Gastrointestinal Disorders (TARGID) at the University of Leuven in Belgium. For several  years, Inge Depoortere has investigated the effect and mechanism of gut peptide action (motilin, ghrelin) in the regulation of gastrointestinal motility and food intake under normal and pathological conditions. Currently, the main focus of her research is on the nutrient sensing mechanisms of endocrine cells in the gut.

 

Daniel Fourmy, PhD

Inserm U858 – I2MR,
Toulouse, France
daniel.fourmy@inserm.fr

Daniel Fourmy has graduated in biochemistry and pharmacology. He is currently Research Director at INSERM and Chief of the INSERM team “Receptors and therapeutic targeting of cancers” affiliated to LPCNO (INSA/CNRS) in Toulouse (http://lpcno.insa-toulouse.fr/). His main fields of investigation are related to G-protein coupled receptors (notably cholecystokinin, gastrin, GIP receptors) in their molecular/structural, pharmacological, signaling, regulation, internalization, functional and pathological aspects. He recently focused his team’s activity towards targeting receptors over-expressed in cancers using targeted magnetic nanoparticles in order to eradicate cancer cells. He has founded the “International Regulatory Peptide Society” in 2006 after having organized the “International Symposium on Regulatory Peptides in Toulouse (2004), and he was president of IRPS until 2014.

 

Jens Peter Goetze, MD, DMSc

Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Jens.Peter.Goetze@regionh.dk

Jens Peter Goetze is Chief Physician at the Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, and Professor of Cardiovascular Endocrinology at Aarhus University, Aarhus (both Denmark). His main research focus is on cardiovascular hormones with an emphasis on cardiac-derived peptides, e.g., the natriuretic peptides.

 

 

 

Karl-Heinz Herzig, MD

Professor at the Department of Physiology, Institute of Biomedicine,
Aapistie 7, Finland.
karl-heinz.herzig@oulu.fi

The team’s research interest is the control of homeostasis via peptides. Understanding the communication of this organ cross talk might decipher the molecular mechanisms in the pathogenesis of metabolic diseases like diabetes and obesity/metabolic syndrome.

 

 

Chris Pemberton, M.Sc. (Hons I), PhD

Christchurch Heart Institute
University of Otago, Christchurch, New Zealand
chris.pemberton@otago.ac.nz

Chris Pemberton is Research Associate Professor at the University of Otago, Christchurch, New Zealand, and a senior member of the Christchurch Heart Institute. He is also Chief Scientific Officer of Upstream Medical Technologies, a cardiac biomarker company. His research interests lie in the discovery of new clinical and research biomarkers, their potential translation to clinical use and the identification of novel biological effects of peptides using ex vivo and in vivo models. Main areas of interest include the natriuretic peptides, troponins, ghrelin and terminal markers of the immune system.

 

Joseph R. Pisegna, MD

Professor of Medicine, UCLA School of Medicine, Chief, Division of Gastroenterology and Hepatology,
VA Greater Los Angeles HCS, USA
jpisegna@ucla.edu

My research interests are focused on understanding the pharmacology, physiology and signal transduction processes for gastrointestinal hormones and their receptors. We have a strong interest in the role of VIP and PACAP in regulating metabolism and obesity.

 

 

Seiji Shioda, PhD

Professor of Peptide Drug Innovation, Global Research Center for Innovative Life Science, Hoshi University, Tokyo, Japan
shioda@hoshi.ac.jp

Seiji Shioda’s main research focus is on neuropeptides with functions in the brain as well as peripheral organs with an emphasis on the design of new therapies for the treatment of dry syndromes as well as brain and spinal cord disorders.

 

 

 

 

Yvette Taché, PhD

Department of Medicine, UCLA,
Los Angeles, CA , USA
ytache@mednet.ucla.edu

Yvette Taché is Professor of Medicine at the UCLA Digestive Diseases Division, and her sustained research area is the role of peptides in brain-gut interaction as it relates to control of gastrointestinal motor function, visceral pain, and food intake. The main focus  is on brain peptides and vagal regulation, and underlying mechanisms of stress-related alteration of gut function and modulation of visceral pain.

 

 

Andrea Varro, MD, PhD

Department of Cell & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
A.Varro@liverpool.ac.uk

Area of expertise: Maintenance of epithelial archictecture in health and disease. Role of gastrin in gastric and oesophageal epthelial cell function. Identification of biomarkers for patients at risk of gastric and oesophageal cancers. Regulation of preneplastic and neoplastic microenvironments; role of stromal cells in modifying the epithelial microenvironment. Contribution of mesenchymal stem cells to epithelial and stromal cell functions.

 

 

Nils Wierup, PhD

Lund University Diabetes Centre
Malmö, Sweden
nils.wierup@med.lu.se

 

 

 

 

 

Michael Wolfe, MD

Professor of Physiology and Biophysics, Chair, Department of Medicine
Case Western Reserve University, MetroHealth Campus, Cleveland, Ohio, USA
michael.wolfe2@case.edu

Michael Wolfe is Chair of the Case Western Reserve University Department of Medicine at MetroHealth Medical Center, Cleveland, OH, USA, where he is also the Charles H. Rammelkamp, Jr. Professor of Medicine. His current research interests include the physiological and pathological significance of glucose-dependent insulinotropic polypeptide (GIP) and specifically its role in the pathogenesis of obesity. He is also conducting research aimed at the use of stem cells programmed to express therapeutic peptides for the treatment of various hereditary and acquired deficiency states.